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Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the
treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci
et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested
in patients with a variety of tumor types and chronic viral diseases. Often, the best way to
assess the clinical potential of these vaccines is to monitor the induced T cell response, and
yet there are currently no standards for reporting these results. This letter is an effort to
address this problem.
In particular, various T cell assays have been developed to try to predict vaccination success
or failure and to ultimately serve as biomarkers and subsequent clinical endpoints in
immunotherapy trials (Hoos et al., 2007). Over the years, a few assays have emerged that
have been widely used, such as ELISPOT, peptide-MHC multimer, and intracellular
cytokine staining (ICS). Yet, these “classical” assays continue to be modified on a regular
basis as additional parameters and innovations in technology are introduced (Chattopadhyay
et al., 2008). Further, an increasing number of innovative therapies and compounds are
moving into clinical trials, and novel monitoring techniques are evolving in step. Because
each new modification has the potential to substantially change the performance
characteristics of a test, results obtained by different centers with slightly modified assays
are likely to vary in ways that are impossible to predict. This compounds the variations in
assay results from facility to facility, as revealed by the outcome of recent multi-institutional
studies for ELISPOT, peptide-MHC multimer, and ICS assays (Figure S1 available online).
The high degree in variability makes the comparison between any two labs becomes a game
of chance. Additional factors that can dramatically impact the performance characteristics of
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assay protocols are related to the analysis, interpretation, and reporting of data and the extent
of quality measures taken to ensure data integrity. To date, no formal quality-control
standards exist for laboratories performing such studies, nor does any requirement for
reporting on such controls. This is in contrast to other, non-immunological types of assays,
such as gene expression arrays.
The importance and influence of these parameters is currently being evaluated through large
ongoing collective initiatives with the goal to enhance bioassay standardization, validation,
and harmonization (Britten et al., 2008). Dedicated conferences and formal sessions at large
international meetings underline the increasing focus on immune-monitoring techniques and
will help to establish these assays as reliable tools to systematically dissect immune
responses in humans and create a reliable foundation for immunotherapy (Davis, 2008).
An area that remains unaddressed by currently published recommendations and guidelines
relates to the establishment of a reporting framework for immune-monitoring assays. It is
clear from the discussion above that the absence of specific information on both the assay
procedure as well as the quality infrastructure of individual laboratories makes it difficult to
interpret results objectively. In only a painfully small number of current publications do the
authors provide sufficient transparency on these points. Hence, it is not surprising that
results are often regarded with skepticism.
In this letter, we introduce the project on “Minimal Information about T Cell Assays”
(MIATA) with recommendations on the minimum specific information required for a more
objective assessment of both the quality of the laboratory infrastructure and the assays
themselves, to allow a thorough interpretation of results from immunological T cell assays.
With this project's introduction, we invite the scientific community to participate in a public
consultation phase. A comprehensive draft document is posted and accessible online
(www.miataproject.org). Feedback will be collected and incorporated during the yearlong
public consultation period and formally discussed in various meetings in order to reach a
consensus document on what the reporting requirements should be. With the assumption that
a broad consensus can be reached, these guidelines will become the framework for a public
database of immune-monitoring data generated in the relevant clinical trials.
We wish to emphasize that MIATA is not intended to impose any particular assays or assay
standards because this would be an obstacle to innovation and improvement of immune-
monitoring technologies. What we wish to define is the content and structure of information
reported from immunoassays. Although reporting frameworks will not per se decrease the
interlaboratory variability found across institutions, they will introduce more transparency to
published data and will allow a reader to judge the quality of reported results, a scenario that
will improve the ability to interpret immune-monitoring results and aid in their adoption.
The current lack of a frameset for reporting data from T cell assays should also be seen in
the context of an increasing number of minimal information projects that have emerged
during the last years. Many of these are listed under the project on Minimum Information for
Biological and Biomedical Investigations (MIBBI) (Taylor et al., 2008). The presently
developed guidelines aim for two major goals: first, to annotate data to such an extent that
they give transparent evidence on the quality, reliability, and possible error sources of
reported results; and second, to use the reporting standards to supply public databases with
more interpretable results (Brazma et al., 2000).
Although some published guidelines touch upon certain aspects of the MIATA project, they
do not fully address the unique features and peculiarities of T cell-based immunoassays, and
no public database for clinical immune-monitoring data yet exists.
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The initial MIATA guideline draft is based on data and reports previously published and
focuses solely on those variables that have been shown to influence the outcome of the three
most commonly used T cell-based immunoassays: ELISPOT, ICS, and peptide-MHC
multimer staining.
The proposed initial publication guidelines of immune-monitoring strategies are based on
the premise that reports of immune-monitoring data generated by the mentioned assays
should accurately include information on and description of five important components that
determine the testing outcome:
1. The sample, including information about the donor or patient (such as age, gender,
human leukocyte antigen (HLA) type, disease, treatment, and comedication as far
as appropriate), techniques used for obtaining, processing, freezing, transporting,
and storing the specimen tested, as well as the way frozen samples were thawed
and quality tested before use in the assay;
2. The assay, including crucial assay techniques, reagents, materials, and equipment
assuring transparency of all assay conditions and, if applicable, a statement of how
publicly available assay recommendations were followed;
3. The data acquisition, including the machines and software used for data acquisition,
their setup and calibration, as well as the strategy to analyze the specific events or
spots;
4. The results, including statistical or empirical response criteria, comments on the
considered biological significance of the obtained results, and comments on
whether the results found can be correlated with a specific disease stage or
treatment;
5. The environment in which laboratory operations are conducted, including the status
of the use of standard operating procedures (SOPs), qualification and/or validation,
compliance with good laboratory practice (GLP), training status of personnel
performing tests, quality-control mechanisms, and responsibilities, as well as
auditing processes and reporting of unexpected events.
Detailed annotation of published data for these five modules should be accompanied by the
reporting of raw data whenever this is needed to guarantee full understanding of the value of
the data set.
A transparent description of procedures and quality measures applied during immune
monitoring is an important step toward achieving proper scientific recognition of reported
data, whether done in a basic research setting or during clinical vaccine testing.
Furthermore, the reporting of minimal information about immunomonitoring assays will
provide an important tool for achieving comparability of results across laboratories and
institutions.
All of our colleagues are invited to actively contribute to the draft guidelines during the
public consultation process. We are aiming at an intensive vetting process that is expected to
lead to substantial changes and a stepwise increase of quality. To reach this goal, we will
actively promote the guidelines and involve organizations and groups as well as other
leaders in the immune-monitoring field, editors of scientific journals, and representatives of
regulatory agencies in a process aiming at reaching a broad consensus for next versions of
the guidelines.
The final goal of our project is to establish a well-vetted and commonly acceptable reporting
standard for immunomonitoring results that could be used to systematically fill an openly
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accessible public database. Such a searchable public repository would be elemental for the
scientific community and drug developers because results could be subjected to comparative
analyses within the context of additional findings reported by colleagues working in a
similar setting.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
S.J. is founder and president of ZellNet Consulting. C.M.B. is a part-time employee at BioNTech AG. H.L. serves
on the Board of Directors of Antigenics and on the Scientific Advisory Board of Celldex. C.J.M.M.is part-time
employed by Immune System Activation (ISA) and possesses stock appreciation rights. A.H. is employed by
Bristol-Myers Squibb.
References
Allison, J.P., Dranoff, G., and Frederick, W. (2006) (San Diego: Elsevier Academic Press).
Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh
J, Watkins DI, Mahmoud A, et al. Science. 2008; 321:530–532. [PubMed: 18653883]
Feldmann M, Steinman L. Nature. 2005; 435:612–619. [PubMed: 15931214]
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N,
Keilholz U, et al. J Immunother. 2007; 30:1–15. [PubMed: 17198079]
Chattopadhyay PK, Hogerkorp CM, Roederer M. Immunology. 2008; 125:441–449. [PubMed:
19137647]
Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Cancer Immunol Immunother.
2008; 57:285–288. [PubMed: 17721782]
Davis MM. Immunity. 2008; 29:835–838. [PubMed: 19100694]
Taylor CF, Field D, Sansone SA, Aerts J, Apweiler R, Ashburner M, Ball CA, Binz PA, Bogue M,
Booth T, et al. Nat Biotechnol. 2008; 26:889–896. [PubMed: 18688244]
Brazma A, Robinson A, Cameron G, Ashburner M. Nature. 2000; 403:699–700. [PubMed: 10693778]
Janetzki et al. Page 4
Immunity. Author manuscript; available in PMC 2013 September 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
